Enveric Biosciences, Inc. (ENVB)
$1.52
+0.05 (+3.40%)
Rating:
Recommendation:
-
| Symbol | ENVB |
|---|---|
| Price | $1.52 |
| Beta | 0.192 |
| Volume Avg. | 0.02M |
| Market Cap | 3.528M |
| Shares () | - |
| 52 Week Range | 1.3-6.98 |
| 1y Target Est | - |
| DCF Unlevered | ENVB DCF -> | |
|---|---|---|
| DCF Levered | ENVB LDCF -> | |
| ROE | -344.02% | Strong Sell |
| ROA | -420.82% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | - | |
| P/E | -0.13 | Neutral |
| P/B | 1.35 | Strong Buy |
Latest ENVB news
About
Download (Excel)Dr. Joseph Edward Tucker Ph.D.
Healthcare
Biotechnology
NASDAQ Capital Market
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.